×
New AI Model ‘ActFound’ Accelerates Drug Discovery
Written by
Published on
Join our daily newsletter for breaking news, product launches and deals, research breakdowns, and other industry-leading AI coverage
Join Now

Breakthrough in bioactivity prediction: A new machine learning model called ActFound demonstrates significant advancements in predicting compound bioactivity, potentially accelerating drug development and discovery processes.

  • ActFound, developed by researchers, is trained on a massive dataset of 1.6 million experimentally measured bioactivities across 35,644 assays from ChEMBL, a comprehensive chemical database.
  • The model employs a novel approach combining pairwise learning and meta-learning to overcome limitations of existing machine learning methods in bioactivity prediction.
  • ActFound shows promise in both accurate in-domain predictions and strong generalization capabilities across various assay types and molecular scaffolds.

Key innovation – pairwise learning approach: ActFound’s unique methodology addresses a critical challenge in bioactivity prediction by focusing on relative differences between compounds within the same assay.

  • This approach circumvents the incompatibility issues among different assays, which have historically hindered the development of generalizable models.
  • By learning relative bioactivity differences, ActFound can make more accurate predictions across a diverse range of chemical compounds and assay types.

Meta-learning optimization: The model further enhances its predictive capabilities through meta-learning techniques, allowing it to learn effectively from a wide array of assays simultaneously.

  • This joint optimization across multiple assays contributes to ActFound’s robust performance and generalization abilities.
  • The meta-learning approach enables the model to capture underlying patterns and relationships in bioactivity data that may not be apparent when focusing on individual assays.

Performance and validation: ActFound’s effectiveness was demonstrated through rigorous testing on six real-world bioactivity datasets, showcasing its potential as a versatile tool for drug discovery.

  • The model exhibited accurate in-domain predictions, indicating its reliability within specific areas of chemical space.
  • More importantly, ActFound showed strong generalization capabilities across different assay types and molecular scaffolds, addressing a key limitation of previous machine learning approaches in this field.

Comparison with physics-based methods: ActFound’s performance was benchmarked against FEP+(OPLS4), a leading physics-based computational tool widely used in drug discovery.

  • The machine learning model achieved comparable performance to FEP+(OPLS4) when fine-tuned with only a few data points.
  • This comparison suggests that ActFound could serve as an accurate and potentially more efficient alternative to traditional physics-based methods in certain bioactivity prediction tasks.

Implications for drug discovery: The development of ActFound represents a significant step forward in applying machine learning to drug development and discovery processes.

  • The model’s ability to make accurate predictions with limited data could accelerate early-stage drug discovery by reducing the need for extensive experimental testing.
  • ActFound’s generalization capabilities may enable researchers to explore a broader chemical space more efficiently, potentially leading to the discovery of novel drug candidates.

Data and code availability: To promote transparency and further research in this area, the researchers have made both the data and code associated with ActFound publicly available.

  • This open approach allows other scientists to validate the results, build upon the work, and potentially integrate ActFound into their own drug discovery pipelines.
  • The availability of the model’s resources could accelerate the adoption of machine learning techniques in the pharmaceutical industry and academic research settings.

Future directions and potential impact: While ActFound shows promise as a bioactivity foundation model, its full potential in real-world drug discovery applications remains to be explored.

  • Further validation studies and integration with existing drug discovery workflows will be crucial to assess the model’s practical impact on the pharmaceutical industry.
  • The success of ActFound may inspire the development of similar foundation models for other aspects of drug discovery, potentially leading to a more comprehensive machine learning-driven approach to pharmaceutical research.
A bioactivity foundation model using pairwise meta-learning

Recent News

Baidu reports steepest revenue drop in 2 years amid slowdown

China's tech giant Baidu saw revenue drop 3% despite major AI investments, signaling broader challenges for the nation's technology sector amid economic headwinds.

How to manage risk in the age of AI

A conversation with Palo Alto Networks CEO about his approach to innovation as new technologies and risks emerge.

How to balance bold, responsible and successful AI deployment

Major companies are establishing AI governance structures and training programs while racing to deploy generative AI for competitive advantage.